{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:42:22Z","timestamp":1793259742255,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40119-023-00346-1","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T12:02:46Z","timestamp":1705060966000},"page":"149-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Add-on Sacubitril\/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3206-6699","authenticated-orcid":false,"given":"Krisztina M\u00e1ria","family":"Szab\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"R\u00e1cz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"P\u00f3lik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Hodosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila C.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Borb\u00e9ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Csan\u00e1di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"346_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"346_CR2","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"2","author":"M Glikson","year":"2021","unstructured":"Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J. 2021;2:3427\u2013520.","journal-title":"Eur Heart J"},{"key":"346_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79:263\u2013421.","journal-title":"J Am Coll Cardiol"},{"key":"346_CR4","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140\u201350.","journal-title":"N Engl J Med"},{"key":"346_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom D, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:14.","journal-title":"N Engl J Med"},{"key":"346_CR6","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ejhf.2046","volume":"22","author":"W Mullens","year":"2020","unstructured":"Mullens W, Auricchio A, Martens P, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Eur J Heart Fail. 2020;22:2349\u201369.","journal-title":"Eur J Heart Fail"},{"key":"346_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacc.2019.09.043","volume":"74","author":"N Varma","year":"2019","unstructured":"Varma N, Boehmer J, Bhargava K, et al. Evaluation management and outcomes of patients poorly responsive to cardiac resynchronization device therapy. J Am Coll Cardiol. 2019;74:21.","journal-title":"J Am Coll Cardiol"},{"key":"346_CR8","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.hrthm.2012.04.024","volume":"9","author":"F Ruschitzka","year":"2012","unstructured":"Ruschitzka F. The challenge of nonresponders to cardiac resynchronization therapy: lessons learned from oncology. Heart Rhythm. 2012;9:S14\u20137.","journal-title":"Heart Rhythm"},{"key":"346_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-018-0407-7","volume":"15","author":"SY Naqvi","year":"2018","unstructured":"Naqvi SY, Jawaid A, Goldenberg I, Kutyifa V. Non-response to cardiac resynchronization. Curr Heart Fail Rep. 2018;15:315\u201321.","journal-title":"Curr Heart Fail Rep"},{"key":"346_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.hrthm.2013.11.025","volume":"11","author":"J Rickard","year":"2014","unstructured":"Rickard J, Cheng A, Spragg D, et al. Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of \u201cnonresponders.\u201d Heart Rhythm. 2014;11:412\u20136.","journal-title":"Heart Rhythm"},{"key":"346_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JV McMurray","year":"2014","unstructured":"McMurray JV, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:11.","journal-title":"N Engl J Med"},{"key":"346_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jjcc.2019.08.005","volume":"75","author":"HY Chang","year":"2020","unstructured":"Chang HY, Chen KC, Fong MC, et al. Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management. J Cardiol. 2020;75:233\u201341.","journal-title":"J Cardiol"},{"key":"346_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi","year":"2019","unstructured":"Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085\u201395.","journal-title":"JAMA"},{"key":"346_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/FJC.0000000000001202","volume":"79","author":"V Russo","year":"2022","unstructured":"Russo V, Ammendola E, Gasperetti A, et al. Add-on therapy with sacubitril\/valsartan and clinical outcomes in CRT-D nonresponder patients. J Cardiovasc Pharmacol. 2022;79:472\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"key":"346_CR15","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1002\/ehf2.12988","volume":"7","author":"KH Chun","year":"2020","unstructured":"Chun KH, Oh J, Yu HT, Lee CJ, et al. The role of sacubitril\/valsartan in the management of cardiac resynchronization therapy non-responders: a retrospective analysis. ESC Heart Fail. 2020;7:4404\u20137.","journal-title":"ESC Heart Fail"},{"key":"346_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5603\/CJ.a2021.0009","volume":"3","author":"JMR Campal","year":"2021","unstructured":"Campal JMR, Castillo H, Rivera BA, et al. Improvement in quality of life with sacubitril\/ \/valsartan in cardiac resynchronization non-responders: the RESINA (RESynchronization plus an Inhibitor of Neprilysin\/Angiotensin) registry. Cardiol J. 2021;3:402\u201310.","journal-title":"Cardiol J"},{"key":"346_CR17","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/j.1540-8159.1996.tb03218.x","volume":"19","author":"S Cazeau","year":"1996","unstructured":"Cazeau S, Ritter P, Lazarus A, et al. Multisite pacing for end-stage heart failure: early experience. Pacing Clin Electrophysiol. 1996;19:1748\u201357.","journal-title":"Pacing Clin Electrophysiol"},{"key":"346_CR18","first-page":"1002","volume":"10","author":"L Maizels","year":"2022","unstructured":"Maizels L, Wasserstrum Y, Fishman B, et al. Characterization of heart failure patients with reverse left ventricular remodeling post-angiotensin receptor blockers\/neprilysin inhibitors therapy. ESC Heart Fail. 2022;10:1002.","journal-title":"ESC Heart Fail"},{"key":"346_CR19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jacc.2019.06.055","volume":"74","author":"JL Januzzi","year":"2019","unstructured":"Januzzi JL, Ahmad T, Mulder H, et al. Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;74:1205\u201317.","journal-title":"J Am Coll Cardiol"},{"key":"346_CR20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","volume":"73","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF Trial. J Am Coll Cardiol. 2019;73:1264\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"346_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2016.09.931","volume":"68","author":"M Zile","year":"2016","unstructured":"Zile M, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68:22.","journal-title":"J Am Coll Cardiol"},{"key":"346_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008410","volume":"14","author":"S Murphy","year":"2021","unstructured":"Murphy S, Prescott MF, Maisel AS, et al. Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers and cardiac remodeling in heart failure with reduced ejection fraction. Circulation Heart Fail. 2021;14:e008410.","journal-title":"Circulation Heart Fail"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-023-00346-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T14:06:46Z","timestamp":1709042806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-023-00346-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1007\/s40119-023-00346-1","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"8 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Krisztina M\u00e1ria Szab\u00f3, Anna T\u00f3th, L\u00e1szl\u00f3 Nagy, Vivien R\u00e1cz, Zs\u00f3fia P\u00f3lik, Katalin Hodosi, Attila C Nagy, Judit Barta, Attila Borb\u00e9ly and Zolt\u00e1n Csan\u00e1di have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Medical Research Council (Ministry of Interior, P.O. Box 314, Budapest, 1903, Hungary) File no. BME\u00dc\/4388-1\/2022\/EKU. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Use of the clinical database was approved by the head of department.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}